The NO Pathway as a Target in Patients with Stable and Advanced Heart Failure: An Additional Arrow in Our Quiver!

Area of Science:

• Cardiovascular Physiology
• Molecular Medicine
• Pharmacology

Background:

• The nitric oxide (NO) pathway, involving soluble guanylate cyclase (sGC) and cyclic guanosine monophosphate (cGMP), regulates vascular tone and cardiac function.
• In heart failure (HF), particularly advanced stages, NO-sGC-cGMP signaling is dysregulated, leading to endothelial dysfunction, fibrosis, and impaired cardiac performance.
• Chronic inflammation in HF further compromises NO bioavailability, worsening disease progression.

Purpose of the Study:

• To review the role of the NO pathway in the pathophysiology of stable and advanced heart failure.
• To evaluate therapeutic strategies targeting NO bioavailability and sGC stimulation in HF.
• To highlight the potential benefits in patient subgroups with comorbidities like chronic kidney disease.

Main Methods:

• Literature review synthesizing current knowledge on NO signaling in HF.
• Analysis of evidence on the impact of impaired NO signaling on cardiac remodeling and function.
• Evaluation of pharmacological interventions aimed at restoring NO levels or activating sGC.

Main Results:

• Impaired NO signaling contributes to vasoconstriction, increased afterload, and adverse cardiac remodeling in HF.
• Therapies restoring NO or stimulating sGC promote vasodilation, reduce fibrosis, and enhance myocardial relaxation.
• These beneficial effects are particularly noted in advanced HF and patients with renal impairment.

Conclusions:

• The NO pathway is a promising therapeutic target for both stable and advanced heart failure.
• Modulating NO signaling can improve cardiovascular outcomes, especially in complex HF patients with comorbidities.
• Further clinical research and tailored treatments targeting the NO pathway are warranted.